Boston Scientific Corporation $BSX Shares Sold by Erste Asset Management GmbH

Erste Asset Management GmbH cut its stake in Boston Scientific Corporation (NYSE:BSX) by 8.0% in the third quarter, Holdings Channel reports. The firm owned 475,166 shares of the medical equipment provider’s stock after selling 41,497 shares during the period. Erste Asset Management GmbH’s holdings in Boston Scientific were worth $46,415,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Boston Scientific during the second quarter valued at $2,089,937,000. Edgewood Management LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at about $746,655,000. Parnassus Investments LLC increased its holdings in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares during the period. Jennison Associates LLC raised its stake in shares of Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BSX. Stifel Nicolaus cut their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Evercore cut their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. JPMorgan Chase & Co. decreased their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Royal Bank Of Canada cut their price target on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Robert W. Baird decreased their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $108.36.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 3.1%

Shares of Boston Scientific stock opened at $75.77 on Friday. The firm has a 50-day simple moving average of $87.69 and a two-hundred day simple moving average of $95.83. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The company has a market cap of $112.43 billion, a P/E ratio of 39.06, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.